# Allergy Therapeutics plc Another strong year of growth

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-plc-another-strong-year-growth/412737006
- Published: 2017-09-28T07:20:23+01:00
- Author: Giles Arbor

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical group specialising in allergy vaccines,
today announced its preliminary results for the year ended 30 June 2017.

**Financial highlights**

· 72% increase in operating profit (pre-R&D) to £7.4m (2016: £4.3m)

· 32% revenue growth increase in actual terms to £64.1m (2016: £48.5m)

· 15%* revenue growth at constant currency to £55.5m (2016: £48.5m)

· 10% compound annual growth in net sales over 18 years

· Market share in the Group’s main European markets increased to 13% (2016: 12%)

· Cash at 30 June £22.1m (2016: £23.4m)

**Operational highlights**

· Commencement of recruitment for pivotal Phase III Pollinex Quattro Birch trial

· US Grass MATA programme proceeding well; safety study successfully completed

· First patient recruited for Acarovac MPL Phase I trial in Spain

· Positive pre-clinical proof of concept trial data announced for Polyvac Peanut

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: “This
has been another strong year of growth with constant currency growth of 15%* increasing
our market share and, together with a favourable sterling/euro exchange rate, boosting
operating profit pre R&D by £3.1m. Our continuing growth and progress on our pipeline
reflects the quality of the products and the committed team that works at Allergy
Therapeutics. We expect further good progress in the coming year.”

 

**CHAIRMAN’S STATEMENT**

**Overview**

I am pleased to introduce the Group’s Annual Report & Accounts for the year ended
30 June 2017. It has been another year of strong and consistent performance across
all areas of the Group. The key areas for value creation remain profitable growth
in European markets, pipeline advancements and paving the way to the significant
US market.

**Performance**

In our European business, sales grew by 15%* in constant currency and we continued
to achieve market share gains, with our market share in markets where we operate
up to 13 % (2016: 12%). This shows an increasing adoption in the market for our 
convenient and patient-friendly treatments compared to other products.

In addition, there has been good progress in the R&D pipeline this year, facilitated
by investment from our growing revenue stream. In March, we announced that we had
recruited the first patient in our pivotal Phase III PQ Birch trial and, in May,
the first patient was recruited for our Acarovac MPL (house dust mite) study. We
announced exciting pre-clinical data from the Polyvac Peanut project in February
and we are pleased that all of the products that the Group has submitted for the
German Therapieallergen-Verordung (TAV) process are continuing to progress well.

We are also making progress with our US commercial strategy. The Grass MATA MPL 
product completed the safety study relating to its higher dose and the Phase II 
Grass trial is due to commence before the end of 2017.

Financially, the Group remains in a robust position with a strong cash balance due
to strong sales growth, aided additionally by the weakening of sterling against 
the euro.

**Board Changes**

There were a number of changes to the Board during the year. In February, we welcomed
US-based Jeff Barton who succeeded Jean-Yves Pavee as Abbott Laboratories’ nominated
director and, in June, Thomas Lander our Board member with extensive R&D experience,
retired from the Board and Tunde Otulana was appointed as a new independent Non-
Executive Director. I thank Jean-Yves and Thomas for their significant contributions
to the Board during their tenures.

Jeff Barton, who is based at Abbott headquarters in Chicago and is VP Licensing 
and Acquisitions, brings extensive commercial experience, especially in the US, 
which will prove vital as the Group continues to execute its global strategy. Tunde
is also based in the US and brings a wealth of global experience in clinical and
regulatory work, particularly with the US Food and Drug Administration (FDA), with
whom he worked for six years earlier in his career. I am delighted to welcome Jeff
and Tunde to the Board.

**Governance**

The Group endeavours to adopt best practice, above normal levels for a company of
its size and sector across the business and it is overseen by an effective and knowledgeable
Board. We are pleased that a regular and transparent dialogue is maintained with
our key stakeholders throughout the year.

* Percentage based on figures in thousands (2017: £55.545m, 2016: £48.509m)

**Looking ahead**

Allergy Therapeutics’ strategy remains clear and focused and it is expected that
the business will continue to grow and its portfolio of products expand in 2018 
and beyond. The Group benefits from a committed, experienced and enthusiastic management
team and the Board and I are confident that we shall continue our successful record
of growth and deliver long-term value creation for shareholders.

On behalf of the Board, I would like to thank all Allergy Therapeutics’ employees
for their commitment and hard work during the year.

Peter Jensen

Chairman

27 September 2017

**CHIEF EXECUTIVE OFFICER’S REVIEW**

**Delivering on our strategy – three areas for growth**

Strong advances have been made this year across all three major strategic objectives.
These are focused around three key pillars of growth: profitably expanding the existing
European business; developing a strong product pipeline, and; preparing for product
entry into the US market.

**European business – milestone CAGR of 10% reached over past 18 years**

The Group reached a significant milestone this year with compound annual growth 
over the past 18 years of 10%. This reflects continued delivery of our focused growth
strategy, innovative products and a robust business model that is resilient to major
economic downturns and significant regulatory changes. The business achieved net
sales of £64.1m, up 15%* at constant currency on the 2016 performance and up 32%
in actual terms.

Following on from the 16% underlying constant rate growth last year, this illustrates
the strength of the Group’s portfolio of convenient, patient-friendly, technically
advanced products and the skilled sales and marketing teams in the business. Whilst
operating in a highly fragmented European allergy market, Allergy Therapeutics continues
to benefit from its innovative approach within this marketplace and will look to
build value for shareholders via suitable corporate development opportunities. The
Group has also continued to invest in its infrastructure, further strengthening 
its supply chain and regulatory functions in anticipation of an increasingly regulated
framework for allergy treatment across the EU and the US. The changes in the regulatory
environment and a drive towards evidence-based products will be to the Group’s advantage.

**Increasing market share**

During the period, the Group continued to increase its market share in the markets
in which we operate, driving this to 13% (2016: 12%) against a broadly flat market
backdrop. In the product portfolio, Pollinex Quattro continues to grow well as patients
and allergists increasingly seek the benefits of our ultra-short course treatment
programs. Venomil, driven by raw material supply issues in the market also grew 
strongly. Acarovac Plus and Probiotics continued to gain market share with the former
being the fastest growing component of the Spanish portfolio.

**Scaling up the business**

A key aim of the management team is to leverage its current infrastructure and this
is demonstrated by the strong increases in revenue and pre-R&D operating profit 
this year in comparison with the prior year.

**Pipeline – Phase III trial underway with broad programmes running**

During the year, the scientific team has been actively managing and preparing for
a number of significant clinical trials. The Pollinex Quattro Birch Phase III trial
received clinical trial application (CTA) approval and recruitment is now well under
way, with treatment of patients ongoing and read out expected in H2 2018. The Grass
MATA MPL development is discussed in more detail below. If the Grass trials are 
successful, they will form part of both the German and US regulatory submissions.

*Percentage based on figures in thousands (2017: £55.545m, 2016: £48.509m)

The products in the German TAV process continue to progress well with plans for 
the start of trials on the oral products and the injectable house dust mite product
in a staggered process starting during the 2018 financial year. The German TAV process
has the potential to boost sales of these products through additional clinical data
as well as reducing the number of competing products in the market.

The Acarovac MPL product for house dust mite allergy has started Phase I trials 
in Spain using the Pollinex Quattro platform technology. This product, if successful
through the trial programme, could become a global best-in-class product with the
first short course subcutaneous treatment in a global market worth an estimated 
$3-4bn [Datamonitor Epidemiology 2011].

The Polyvac Peanut product completed a positive pre-clinical trial showing impressive
protective immunity with a single vaccination and no anaphylaxis. This product uses
the virus like particle (VLP) technology that the business acquired to create a 
subcutaneous product that could offer long lasting protective immunity for subjects
with peanut allergy, rather than just increasing tolerability in the case of accidental
exposure.

**Team – expanding the scientific excellence**

In order to facilitate continued success in the clinical development programme, 
the Group is strengthening the organisation with expansion of the clinical team 
led by Murray Skinner, Chief Scientific Officer at the Group’s UK headquarters in
Worthing. The Group has underlined its commitment to clinical excellence by appointing
Pieter-Jan de Kam as Clinical Director in mid-September. Pieter-Jan de Kam joined
the Group from HAL Allergy in the Netherlands where he was responsible for clinical
development with recent successes including European and US studies for pollen and
house dust mites.

In addition to the appointment of Pieter-Jan, the Group has recruited Simon Piggott
as Head of Clinical Science. Simon will be responsible for the delivery of a robust
clinical strategy bridging the gap between the Groups’ existing product development
teams and clinical departments. Simon has significant experience in successful development
programs from time spent at Novartis, GSK and most recently at Quintiles. Tim Higenbottam
has been appointed to the role of Senior Pharmaceutical Physician and will focus
on the US regulatory process.

The Group is continuing to invest in the R&D function to drive the key pipeline 
trials. The overall headcount in the research and development function within the
Group has doubled in the last two years.

**Publication of data – validating the Bencard Adjuvant Systems division**

During the year, two papers were published in peer-reviewed journals reporting on
new pre-clinical studies from the Group’s Bencard Adjuvant Systems (BAS) division.
The two papers report that the novel depot adjuvant behind the Pollinex platform,
micro-crystalline tyrosine (MCT), both alone and in an adjuvant system, have broad
applications and elicit high, sustained antibody levels demonstrating enhanced protective
efficacy compared to conventional adjuvants including aluminium. MCT has now been
granted manufacturing patents in the US, Europe and Japan.

**US market – changing environment will drive market share towards Allergy Therapeutics**

The US market for allergic rhinitis, which is estimated to be worth $2bn [internal
estimate], continues to evolve. The regulatory pressures in the US that the Group
acknowledged last year are becoming stronger as the FDA and the US Pharmacopeial
Convention (USP) set strict guidelines for compounding and dispensing of allergy
products. These guidelines, if fully implemented, will drive the market towards 
pharmaceutical grade, centrally manufactured products that should benefit businesses
like Allergy Therapeutics with GMP, MHRA-approved facilities. Given the widespread
adoption of subcutaneous immunotherapy (SCIT) treatments in the US, the oral products
that are currently in the US market have so far not achieved a significant share
leaving the market open for new entrants, such as Allergy Therapeutics, with the
right products, manufacturing capability and commercial approach. The Group continues
to prepare its portfolio of products for capturing the significant US market opportunity.

The Grass MATA MPL product, which is in development, has completed a safety study
relating to a new higher dose and the Phase II trial is expected to start in the
autumn. Following completion of this trial, meetings with the regulatory authorities
in the US and Germany will be necessary before it progresses to a Phase III trial.

**Outlook – confidence across the business**

Allergy Therapeutics’ management team expects 2018 to be a pivotal year with significant
results due across a number of key programs. Revenue for 2018 is again set to show
continued growth at constant currency, driven by further penetration of the market
by the Group’s convenient ultra-short course treatment. Gross margins are likely
to improve slightly as volumes grow. Overheads will rise less in 2018 than they 
did in 2017 as investment slows, based on constant currency rates. However, as previously
disclosed, we anticipate research and development expenditure is likely to almost
double as the Group commences the PQ Birch Phase III and Grass MATA MPL Phase II
studies and continues to invest in new product development.

The Group expects the results of both the PQ Birch Phase III trial, the first pivotal
Phase III trial for a Pollinex Quattro product in Europe, and the results of the
Grass Mata MPL Phase II trial in H2 2018.

The Board and the executive team remains confident about the Group’s future growth
potential and remains focused on generating significant value for shareholders given
its continued sales momentum, the robust research pipeline progress driven by the
strengthened research and development team and the potential of the US product portfolio
as we prepare the ground for the future.

Manuel Llobet – CEO – Allergy Therapeutics plc

27 September 2017

Share on:
